These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9145209)

  • 41. The effect of food on the oral bioavailability and the pharmacodynamic actions of the insulinotropic agent nateglinide in healthy subjects.
    Karara AH; Dunning BE; McLeod JF
    J Clin Pharmacol; 1999 Feb; 39(2):172-9. PubMed ID: 11563410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Nateglinide improves early insulin secretion and controls postprandial glucose excursions in a prediabetic population.
    Saloranta C; Guitard C; Pecher E; De Pablos-Velasco P; Lahti K; Brunel P; Groop L
    Diabetes Care; 2002 Dec; 25(12):2141-6. PubMed ID: 12453951
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
    Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
    Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of the combination of a dipeptidyl peptidase IV inhibitor and an insulin secretagogue on glucose and insulin levels in mice and rats.
    Yamazaki K; Yasuda N; Inoue T; Yamamoto E; Sugaya Y; Nagakura T; Shinoda M; Clark R; Saeki T; Tanaka I
    J Pharmacol Exp Ther; 2007 Feb; 320(2):738-46. PubMed ID: 17093132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Differential effects of short and long duration insulinotropic agents on meal-related glucose excursions.
    de Souza CJ; Russo P; Lozito R; Dunning BE
    Diabetes Obes Metab; 2001 Apr; 3(2):73-83. PubMed ID: 11298729
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats.
    Fujimori Y; Katsuno K; Ojima K; Nakashima I; Nakano S; Ishikawa-Takemura Y; Kusama H; Isaji M
    Eur J Pharmacol; 2009 May; 609(1-3):148-54. PubMed ID: 19281809
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.
    Ishida H; Kato S; Nishimura M; Mizuno N; Fujimoto S; Mukai E; Kajikawa M; Yamada Y; Odaka H; Ikeda H; Seino Y
    Horm Metab Res; 1998 Nov; 30(11):673-8. PubMed ID: 9918384
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.
    Kalbag JB; Walter YH; Nedelman JR; McLeod JF
    Diabetes Care; 2001 Jan; 24(1):73-7. PubMed ID: 11194245
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
    Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
    Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sulfonylurea induced beta-cell apoptosis in cultured human islets.
    Maedler K; Carr RD; Bosco D; Zuellig RA; Berney T; Donath MY
    J Clin Endocrinol Metab; 2005 Jan; 90(1):501-6. PubMed ID: 15483097
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
    Abdel-Zaher AO; Ahmed IT; El-Koussi AD
    Pharmacol Res; 2001 Nov; 44(5):397-409. PubMed ID: 11712871
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effect of the new oral hypoglycemic agent A-4166 on glucose turnover in the high fat diet-induced and/or in the hereditary insulin resistance of rats.
    Klimes I; Mitková A; Gasperíková D; Ukropec J; Líska B; Bohov P; Stanek J; Seböková E
    Arch Physiol Biochem; 1998 Oct; 106(4):325-32. PubMed ID: 10417860
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of timing of administration and meal composition on the pharmacokinetic and pharmacodynamic characteristics of the short-acting oral hypoglycemic agent nateglinide in healthy subjects.
    Luzio SD; Anderson DM; Owens DR
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4874-80. PubMed ID: 11600556
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
    Kotapati S
    Conn Med; 2002 May; 66(5):269-72. PubMed ID: 12071108
    [No Abstract]   [Full Text] [Related]  

  • 57. [Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
    Nagashima K; Inagaki N
    Nihon Naika Gakkai Zasshi; 2009 Apr; 98(4):737-41. PubMed ID: 19472523
    [No Abstract]   [Full Text] [Related]  

  • 58. The effect on plasma glucose, insulin and glucagon levels of treatment of diabetic rats with the medicinal plant Rhazya stricta and with glibenclamide, alone and in combination.
    Ali BH
    J Pharm Pharmacol; 1997 Oct; 49(10):1003-7. PubMed ID: 9364411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus.
    Ono Y; Kameda H; Cho KY
    Expert Opin Pharmacother; 2013 Mar; 14(4):361-70. PubMed ID: 23414242
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.